Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol

Objective: To compare the efficacy of milrinone and dobutamine in patients chronically treated with carvedilol. Background: Milrinone and dobutamine are used to manage decompensated heart failure, but their efficacy in patients on beta-blocker therapy was unknown. Methods: Twenty patients with decompensated heart failure were prospectively enrolled. Inotropic responses to milrinone (12.5, 25 or 50 mug/kg bolus infusions) or dobutamine (5, 10, 15 or 20 mug/kg/min infusions) were evaluated by right-heart catheterization. Results: Milrinone increased cardiac index (2.0-2.6 1/min/m(2), P=0.0001) without significantly altering heart rate (70-75 bpm, P=0.19). Milrinone decreased mean pulmonary artery pressure (36-29 mm Hg, P=0.0001), pulmonary capillary wedge pressure (24-18 mm Hg, P=0.0001) and mean arterial blood pressure (78-75 mm Hg, P=0.0002). Left ventricular stroke volume index increased in the milrinone group (31-35 ml/beat/m(2), P=0.0001). Dobutamine produced an increase in cardiac index (2.4-3.3 1/min/m(2), P=0.0001) only at doses that are not typically used to treat heart failure (15-20 mug/kg/min). At these doses, dobutamine increased heart rate (68-82 bpm, P=0.008), mean systemic pressure (90-117 mm Hg, P=0.0001) and mean pulmonary artery pressure (21-30 mm Hg, P=0.001). Dobutamine did not alter left ventricular stroke volume index or pulmonary capillary wedge pressure. Conclusions: Dobutamine and milrinone have different hemodynamic effects in patients treated chronically with carvedilol. These differences should be considered when selecting inotropic therapy for decompensated heart failure. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.